{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Notarika%2C%20S.A.%20de%20C.V.","name":"Notarika, S.A. de C.V.","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-04T15:05:45.089Z"},"count":1,"matches":[{"id":"efed35efc6e085a9","posted_date":"2021-10-12","letter_issue_date":"2021-10-07","company_name":"Notarika, S.A. de C.V.","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/efed35efc6e085a9"}]}